404 related articles for article (PubMed ID: 37834411)
1. Epigenetic Modulators as Therapeutic Agents in Cancer.
Patnaik E; Madu C; Lu Y
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834411
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Priming and Development of New Combination Therapy Approaches.
Meneceur S; Grunewald CM; Niegisch G; Hoffmann MJ
Methods Mol Biol; 2023; 2684():259-281. PubMed ID: 37410240
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.
Ganesan A; Nolan L; Crabb SJ; Packham G
Curr Cancer Drug Targets; 2009 Dec; 9(8):963-81. PubMed ID: 20025605
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
[TBL] [Abstract][Full Text] [Related]
7. Targeting epigenetic DNA and histone modifications to treat kidney disease.
Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer.
Gutiérrez JR; Salgado ARM; Arias MÁ; San-Juan-Vergara H; Rada WR; Gómez CMM
Curr Med Chem; 2022; 29(9):1503-1542. PubMed ID: 34963430
[TBL] [Abstract][Full Text] [Related]
9. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modifications in prostate cancer.
Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
[TBL] [Abstract][Full Text] [Related]
11. [Development of novel epigenetic molecular-targeting agents].
Sowa Y; Sakai T
Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
[TBL] [Abstract][Full Text] [Related]
13. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Cang S; Ma Y; Liu D
J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
[TBL] [Abstract][Full Text] [Related]
14. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modulators as therapeutic targets in prostate cancer.
Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy.
Biswas S; Rao CM
Eur J Pharmacol; 2018 Oct; 837():8-24. PubMed ID: 30125562
[TBL] [Abstract][Full Text] [Related]
17. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
